Results 21 to 30 of about 36,696 (303)

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor II [PDF]

open access: yes, 1994
Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to β-cell membranes with 8–9-fold higher koff rate and 2.5–3-fold higher kon rate compared to glibenclamide (see ...
Aguilar-Bryan   +29 more
core   +1 more source

Transcription factor 7-like 2 rs7903146 polymorphism and therapeutic response to sulfonylureas in patients with type 2 diabetes

open access: yesJournal of Medicine in Scientific Research, 2018
Background Transcription factor 7-like 2 (TCF7L2) variations were related to a modified hypoglycemic reaction to sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2D).
Ghada A Omar   +3 more
doaj   +1 more source

Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group [PDF]

open access: yes, 2018
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease.
Avery, C.L.   +58 more
core   +4 more sources

Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus

open access: yesEndocrinology, Diabetes & Metabolism, 2022
Aims Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID‐19). The effect of T2DM medications on COVID‐19 outcomes remains unclear.
Jinghong Li   +12 more
doaj   +1 more source

Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction

open access: yesFrontiers in Cardiovascular Medicine, 2021
Aims: This retrospective study assessed the association between sulfonylureas use and infarct size in patients with type 2 diabetes (T2DM) and ST-segment elevation myocardial infarction (STEMI) by myocardial enzymology indexes and cardiac magnetic ...
Fang-Hong Shi   +7 more
doaj   +1 more source

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]

open access: yes, 2016
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila   +2 more
core   +2 more sources

Injúria potencial de herbicidas de solo ao girassol: II - chlorimuron-ethyl Potential suflower injury by soil applied herbicides: II - chlorimuron-ethyl

open access: yesPlanta Daninha, 1993
Conduziu-se um ensaio de campo na Estação Experimental Agronômica da Universidade Federal do Rio Grande do Sul, em Eldorado do Sul, RS em 1989/90. O objetivo do trabalho foi determinar o efeito residual potencial do herbicida chlorimuron-ethyl aplicado ...
Nilson G. Fleck, Ribas A. Vidal
doaj   +1 more source

ABIOTIC DEGRADATION OF IODOSULFURON-METHYL-ESTER IN AQUEOUS SOLUTION [PDF]

open access: yes, 2005
The abiotic degradation of iodosulfuron-methyl-ester was investigated under both alkaline and acidic pH conditions in the dark, and results showed it to be a rather stable molecule in neutral or slightly alkaline environments.
C. EMMELIN   +4 more
core   +1 more source

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

open access: yesСахарный диабет, 2011
In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing ...
Alla Vsevolodovna Rudakova
doaj   +1 more source

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. [PDF]

open access: yes, 2016
ObjectiveTo examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe hypoglycemia among patients with type 2 diabetes (T2DM).Research design and methodsUsing claims data from 1.66 million privately ...
Gill, Thomas M   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy